Surbiton Medical Ltd 14621792 false 2023-01-27 2024-03-31 2024-03-31 The principal activity of the company is general medical practice activities. Digita Accounts Production Advanced 6.30.9574.0 true true 14621792 2023-01-27 2024-03-31 14621792 2024-03-31 14621792 core:RetainedEarningsAccumulatedLosses 2024-03-31 14621792 core:ShareCapital 2024-03-31 14621792 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 14621792 bus:SmallEntities 2023-01-27 2024-03-31 14621792 bus:AuditExemptWithAccountantsReport 2023-01-27 2024-03-31 14621792 bus:FullAccounts 2023-01-27 2024-03-31 14621792 bus:SmallCompaniesRegimeForAccounts 2023-01-27 2024-03-31 14621792 bus:RegisteredOffice 2023-01-27 2024-03-31 14621792 bus:Director1 2023-01-27 2024-03-31 14621792 bus:Director2 2023-01-27 2024-03-31 14621792 bus:Director3 2023-01-27 2024-03-31 14621792 bus:PrivateLimitedCompanyLtd 2023-01-27 2024-03-31 14621792 1 2023-01-27 2024-03-31 14621792 countries:AllCountries 2023-01-27 2024-03-31 iso4217:GBP xbrli:pure

Registration number: 14621792

Surbiton Medical Ltd

Annual Report and Unaudited Filleted Abridged Financial Statements

for the Period from 27 January 2023 to 31 March 2024

 

Surbiton Medical Ltd

Contents

Abridged Balance Sheet

1

Notes to the Unaudited Abridged Financial Statements

2

 

Surbiton Medical Ltd

(Registration number: 14621792)
Abridged Balance Sheet as at 31 March 2024

Note

2024
£

Current assets

 

Cash at bank and in hand

 

9,861

Creditors: Amounts falling due within one year

(10,300)

Net liabilities

 

(439)

Capital and reserves

 

Called up share capital

300

Profit and loss account

(739)

Total equity

 

(439)

For the financial period ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 23 October 2024 and signed on its behalf by:
 

Dr P D Moore

Director

Dr N S N Mansour

Director

Dr J M Edwards

Director

 

Surbiton Medical Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 27 January 2023 to 31 March 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
Calyx House
South Road
Taunton
Somerset
TA1 3DU

These financial statements were authorised for issue by the Board on 23 October 2024.

2

Accounting policies

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Disclosure of long or short period

The accounts prepared are for a period greater than one year, this is due to this being the first set of accounts prepared for the company since it was incorporated. There is therefore no comparative period for the accounts available.

Going concern

The financial statements have been prepared on a going concern basis. The Directors have offered their financial support to enable the company to meet its liabilities as they fall due for the foreseeable future.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 3.